机译:CTDNA作为局部晚期直肠癌患者的潜在预后标志物,接受Neoadjuvant Chemo-adrigation治疗无病生存(DFS)
Fudan Univ Shanghai Canc Ctr Dept Radiat Oncol Shanghai Peoples R China;
Shanghai Canc Ctr Shanghai Peoples R China;
Fudan Univ Shanghai Canc Ctr Dept Radiat Oncol Shanghai Peoples R China;
Geneseeq Technol Inc Translat Med Res Inst Toronto ON Canada;
Nanjing Geneseeq Technol Inc Dept Med Nanjing Jiangsu Peoples R China;
Fudan Univ Shanghai Canc Ctr Dept Radiat Oncol Shanghai Peoples R China;
Fudan Univ Huashan Hosp Shanghai Peoples R China;
Geneseeq Technol Inc Translat Med Res Inst Toronto ON Canada;
Geneseeq Technol Inc Translat Med Res Inst Toronto ON Canada;
Fudan Univ Shanghai Canc Ctr Dept Radiat Oncol Shanghai Peoples R China;
Fudan Univ Shanghai Canc Ctr Dept Radiat Oncol Shanghai Peoples R China;
机译:CTDNA作为局部晚期直肠癌患者的潜在预后标志物,接受Neoadjuvant Chemo-adrigation治疗无病生存(DFS)
机译:PI3K / PTEN / AKT / mTOR途径的遗传变异可预测接受术前放化疗和根治性手术的局部晚期直肠癌患者的肿瘤反应和无病生存
机译:Neoadjuvant ChemoRadiOurapy疗法患者肿瘤回归等级和肿瘤回归等级和产量病理TNM阶段的肿瘤回归等级及产量病理TNM阶段的预后影响
机译:Neoadjuvant在直肠癌中治疗:我们总是需要放射治疗 - 或者我们是否可以更好地评估当地先进的直肠癌?
机译:强烈的Neoadjuvant治疗局部晚期癌症射线=加强Neoadjuvant治疗局部晚期直肠癌
机译:Transketolase like gene 1(TKTL1)的表达预测接受新辅助放化疗的局部晚期直肠癌患者的无病生存
机译:CTDNA作为局部晚期直肠癌患者的潜在预后标志物,接受Neoadjuvant Chemo-adrigation治疗无病生存(DFS)